Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Next Previous
Trial Profile

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 5335 (Primary) ; Saruparib (Primary) ; Bevacizumab; Carboplatin
  • Indications Adenocarcinoma; Lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms FONTANA
  • Sponsors AstraZeneca

Most Recent Events

  • 29 Jun 2025 Given protocol has been amended as above-1) Number of treatment arms has been changed from 4 to 5. 2) Planned number of patients has been changed from 396 to 446.
  • 29 Jun 2025 Planned number of patients changed from 396 to 446.
  • 10 Oct 2024 Planned number of patients changed from 150 to 396.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top